Takeshi Kimura, Takeshi Morimoto, Yutaka Furukawa, Yoshihisa Nakagawa, Kazushige Kadota, Masashi Iwabuchi, Satoshi Shizuta, Hiroki Shiomi, Tomohisa Tada, Junichi Tazaki, Yoshihiro Kato, Mamoru Hayano, Mitsuru Abe, Takashi Tamura, Manabu Shirotani, Shinji Miki, Mitsuo Matsuda, Mamoru Takahashi, Katsuhisa Ishii, Masaru Tanaka, Takeshi Aoyama, Osamu Doi, Ryuichi Hattori, Ryozo Tatami, Satoru Suwa, Akinori Takizawa, Yoshiki Takatsu, Masaaki Takahashi, Hiroshi Kato, Teruki Takeda, Jong-Dae Lee, Ryuji Nohara, Hisao Ogawa, Chuwa Tei, Minoru Horie, Hirofumi Kambara, Hisayoshi Fujiwara, Kazuaki Mitsudo, Masakiyo Nobuyoshi, Toru Kita
Long-term safety and efficacy of drug-eluting stents remains controversial. The CREDO-Kyoto registry cohort-2 is a physician-initiated non-company sponsored multi-center registry enrolling consecutive patients undergoing first coronary revascularization in 26 centers in Japan. We compared 3-year outcome between patients treated with sirolimus-eluting stent (SES) only (5092 patients) and bare-metal stent (BMS) only (5405 patients). SES-use as compared with BMS-use was associated with significantly lower adjusted risk for all-cause death [hazard ratio (HR) [95% confidence interval (CI)] 0...
September 2011: Cardiovascular Intervention and Therapeutics